Atrial fibrillation is the most common sustained heart rhythm disorder and a growing epidemic in an aging population. Unfortunately, current therapies have proven ineffective for many patients as they do not address the underlying mechanisms of the disease.

At Inomagen, we are exclusively focused on discovering and developing transformative gene therapies to markedly improve the treatment of atrial fibrillation. Our scientific advancements have been the result of significant non-dilutive grant funding. The company has an exclusive license agreement with Northwestern University for a robust IP estate and has assembled a highly experienced team to bring our therapies to market.

Inomagen Therapeutics

Org chart

Teams

Offices